All studies
Active not recruitingPHASE1INTERVENTIONAL

A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec

This research study aims to understand a new medicine, BIIB115, for spinal muscular atrophy (SMA). It begins by testing the safety and how the body processes BIIB115 in healthy adult men. The next part focuses on children with SMA who have previously received a different SMA treatment. Doctors want to find out how many people experience side effects and how BIIB115 moves through the body, including in the fluid around the brain and spinal cord. The study involves injections of BIIB115 into the spinal canal and includes different groups, some receiving a dummy medicine (placebo). It will last for several months, with clinic visits and phone calls, to carefully monitor participants' health.

At a glance

Status
Active not recruiting
Phase
PHASE1
Sponsor
Biogen
Enrolment target
62
Start
10 Oct 2022
Estimated completion
14 Nov 2031

What is this study about?

This study is looking into a new medicine called BIIB115, which could potentially help people with spinal muscular atrophy (SMA). SMA is a genetic condition that affects nerve cells, leading to muscle weakness and problems with movement. The main goal of this research is to see how safe BIIB115 is and how the body handles it, making sure it's as safe as possible before it can be used more widely.

The study is split into two main parts. The first part involves healthy adult men. They will receive a single injection of either BIIB115 or a placebo, which looks like the real medicine but contains no active drug. This helps researchers understand the medicine's basic safety and how it moves through the body without the complications of the condition itself. Neither the participants nor the doctors will know who gets the real medicine and who gets the placebo, which helps to keep the results fair and unbiased.

The second part of the study focuses on children with SMA who have already had another important SMA treatment. These children will receive doses of BIIB115, and the doctors will carefully watch for any side effects and learn more about how the medicine works in their bodies over a longer period. This part is crucial because it helps doctors understand how BIIB115 might specifically benefit children dealing with SMA.

Key takeaways

  • This study is testing a new medicine, BIIB115, for Spinal Muscular Atrophy (SMA).
  • It first checks the medicine's safety in healthy men, then in children with SMA.
  • BIIB115 is given by injection into the spinal fluid.
  • Researchers are carefully monitoring for side effects and how the body processes the medicine.
  • Participation involves clinic visits, injections, and follow-up phone calls over several months.
  • You can stop participating at any time.

Who may be eligible?

This study is looking for two main groups of people. For the first part of the study, they need healthy men, aged between 18 and 55, who are generally in good health.

For the second part, they are looking for children with SMA who are between 6 months and 12 years old. These children must have a confirmed genetic diagnosis of SMA and weigh at least 7 kg. It's also important that they have previously received a treatment called onasemnogene abeparvovec at least 180 days before potentially starting BIIB115, and doctors believe their SMA could still improve.

You would not be able to join if you have any health problems that would make a spinal injection risky, have certain serious medical conditions, or have had a serious infection recently. The doctors will check your medical history very carefully to make sure it's safe for you to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you a healthy man between 18 and 55 years old?
  2. Is the child with SMA between 6 months and 12 years old and weighs at least 7kg?
  3. Has the child with SMA been diagnosed with 5q SMA genetically?
  4. Has the child with SMA already received the medicine `onasemnogene abeparvovec` at least 6 months ago?
  5. Does your doctor think your SMA could still improve?
  6. Do you have any serious health conditions that could make a spinal injection risky?
Answer every question to see your result.

What does participation involve?

If you decide to take part, the study will involve several visits to a clinic and some phone calls. For healthy adult men in Part A, you'll have up to 6 clinic visits and 4 phone calls over 13 months. You'll receive a single injection into your spinal canal on Day 1. You won't know if you're getting the actual medicine or a dummy injection. After this injection, you'll stay in the clinic for 24 hours so doctors can monitor you closely.

For children with SMA in Part B, the study lasts 24 months, with up to 14 clinic visits and 6 phone calls. You'll receive two injections of BIIB115 over this period, and everyone will know you're getting the active medicine. Again, there will be a 24-hour stay in the clinic after each injection. After completing Part B, some children might have the option to join a long-term follow-up called the LTE, which involves five more doses of BIIB115 and lasts for another 60 months, with additional clinic visits and phone calls. Please note that the 24-hour clinic stay after injections is not typically required in the LTE.

Potential risks and benefits

Taking part in any study has potential benefits and risks. You might not directly benefit from taking part, but your involvement could help doctors learn more about SMA and potentially develop new treatments for others in the future. As for risks, every medical procedure carries some risks, and a spinal injection is no different. Doctors will be looking out for any unwanted health problems, sometimes called 'adverse events,' which may or may not be related to the study medicine. It's important to remember that you have the right to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (17)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • Universitair Ziekenhuis Gent
    Verified postcode
    Ghent, Belgium
  • Children's Hospital of Eastern Ontario
    Unverified
    Ontario, Canada
  • Hôpital Armand Trousseau
    Verified postcode
    Paris, France
  • Universitatsklinikum Essen
    Verified postcode
    Essen, Germany
  • Universitaetsklinikum Freiburg
    Verified postcode
    Freiburg im Breisgau, Germany
  • Universitaetsklinikum Heidelberg
    Verified postcode
    Heidelberg, Germany
  • Fondazione Serena Onlus - Centro Clinico Nemo
    Verified postcode
    Milan, Italy
  • Pediatric Neurology Unit, Catholic University
    Verified postcode
    Rome, Italy
  • Centre For Human Drug Research
    Verified postcode
    Leiden, Netherlands
  • UMC Utrecht
    Verified postcode
    Utrecht, Netherlands
  • Instytut Centrum Zdrowia Matki Polki Dept of Neurology
    Verified postcode
    Lodz, Poland
  • PRATIA S.A. MTZ Clinical Research Powered by Pratia
    Verified postcode
    Warsaw, Poland

Common questions

What is SMA?

SMA stands for Spinal Muscular Atrophy, a genetic condition that causes muscles to become weak because certain nerve cells don't work properly.

What is BIIB115?

BIIB115 is a new medicine being studied to see if it can help people with Spinal Muscular Atrophy.

What is a placebo?

A placebo is a dummy treatment that looks exactly like the real medicine but contains no active drug. It helps researchers compare the real medicine's effects.

How is the study medicine given?

The medicine is given as an injection directly into the fluid around the spinal cord, often called a 'spinal tap'.

Can I leave the study if I change my mind?

Yes, you are free to leave the study at any time, for any reason, and it will not affect your ongoing medical care.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.